PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025.
'Our EDO platform's unique ability to efficiently deliver oligonucleotides into the nuclei of cells is the foundation of our differentiated pipeline, with promising clinical data from two programs underscoring what we believe to be the broad potential of our technology,' said James McArthur, PhD, President and CEO of PepGen. 'This is a pivotal and catalyst-rich 12 months for PepGen and for our DM1 and DMD clinical programs. Following the highly encouraging initial results from our FREEDOM-DM1 study reported in February, demonstrating potentially best-in-class splicing correction after a single therapeutic dose, we look forward to sharing data from the 15 mg/kg cohort in the second half of the year. We also expect to report dystrophin production data from the 10 mg/kg cohort of our CONNECT1-EDO51 study in patients with DMD in the third quarter. Collectively, we believe these data will build on the body of evidence supporting our platform's promise. Additionally, during the first quarter, we have undertaken various measures to extend our cash runway while prioritizing delivering on our key clinical milestones.'
Recent Program Updates
PGN-EDODM1: Myotonic Dystrophy Type 1 (DM1)
Phase 1 FREEDOM-DM1 Single Ascending Dose (SAD) Randomized, Placebo-Controlled Clinical Trial of PGN-EDODM1:
In February, the Company reported positive initial clinical data from the 5 mg/kg and 10 mg/kg dose cohorts from the ongoing FREEDOM trial. At day 28 following a single dose, PGN-EDODM1 was observed to have a favorable emerging safety profile and robust, dose-dependent splicing correction in the 5 and 10 mg/kg dose cohorts.
PepGen expects to report safety, 28-day splicing and functional benefit data from the 15 mg/kg cohort during the second half of 2025.
Phase 2 FREEDOM2-DM1 Multiple Ascending Dose (MAD) Randomized, Placebo-Controlled Clinical Trial of PGN-EDODM1:
The Company expects to report results from the 5 mg/kg cohort of the FREEDOM2 trial in the first quarter of 2026.
PGN-EDO51: Duchenne Muscular Dystrophy (DMD)
Phase 2 CONNECT1-EDO51 Open-Label MAD Clinical Trial of PGN-EDO51:
PepGen expects to report additional safety as well as dystrophin production data from the 10 mg/kg cohort of the CONNECT1 trial in DMD patients in the third quarter of 2025.
Phase 2 CONNECT2-EDO51 MAD Clinical Trial of PGN-EDO51:
In March 2025, the Company announced its voluntary decision to pause the Phase 2 CONNECT2 trial in DMD patients until it can review results from the 10 mg/kg cohort in the ongoing Phase 2 CONNECT1 trial.
Corporate Updates
In March 2025, PepGen announced that Lisa Wyman and Mitchell H. Finer, PhD, joined the Company's Board of Directors. Each are industry veterans bringing decades of executive and operational experience in life sciences to the Company.
In March 2025, the Company gave two oral presentations and presented five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The oral presentations featured data from the ongoing CONNECT1 clinical trial in DMD and the FREEDOM clinical trial in DM1.
In May 2025, the Company made an oral presentation and presented two posters at the 2025 Myotonic Dystrophy Foundation (MDF) Conference. PepGen also presented at the 5 th Edition of Euro-DyMA's Pharma Day, held in conjunction with the MDF Conference. These presentations highlighted the recently announced FREEDOM clinical data in DM1, as well as proof-of-mechanism preclinical results for PGN-EDODM1.
Financial Results for the Three Months Ended March 31, 2025
Cash, Cash Equivalents and Marketable Securities were $97.8 million as of March 31, 2025. Based on currently planned operations, the Company believes that its existing cash, cash, equivalents, and marketable securities will be sufficient to fund its operations for at least 12 months from the date of this release.
Research and Development Expenses were $25.4 million for the three months ended March 31, 2025, compared to $14.7 million for the same period in 2024.
General and Administrative Expenses were $5.9 million for the three months ended March 31, 2025, compared to $5.1 million for the same period in 2024.
Net Loss was $30.2 million, or $(0.92) basic and diluted net loss per share, for the three months ended March 31, 2025, compared to $18.0 million, or $(0.63) basic and diluted net loss per share, for the same period in 2024. PepGen had approximately 32.7 million shares outstanding on March 31, 2025.
Upcoming Potential Milestones
3Q 2025: CONNECT1-EDO51 data from 10 mg/kg cohort expected
2H 2025: FREEDOM-DM1 data from 15 mg/kg cohort expected
1Q 2026: FREEDOM2-DM1 data from the 5 mg/kg cohort expected
About PGN-EDODM1
PGN-EDODM1, PepGen's investigational candidate in development for the treatment of DM1, utilizes the Company's proprietary Enhanced Delivery Oligonucleotide (EDO) technology to deliver a therapeutic oligonucleotide that is designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. DM1 is a progressively disabling, life-shortening genetic disorder. DM1 is estimated to affect 40,000 people in the United States, and over 74,000 people in Europe. The U.S. Food and Drug Administration has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for the treatment of patients with DM1.
About PGN-EDO51
PGN-EDO51, PepGen's investigational candidate in development for the treatment of DMD, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to target the root cause of this devastating disease. PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, an established therapeutic target for approximately 13% of DMD patients, thereby aiming to restore the open reading frame and enabling the production of a truncated, yet functional dystrophin protein. The U.S. Food and Drug Administration has granted PGN-EDO51 both Orphan Drug and Rare Pediatric Disease Designations for the treatment of patients with DMD amenable to an exon-51 skipping approach.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen's EDO platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the therapeutic potential and safety profile of our product candidates, including, based on early data, PGN-EDODM1 and PGN-EDO51, the expected timing for additional data reports from our FREEDOM Phase 1 trial and CONNECT1 Phase 2 trial and initial data from our FREEDOM2 Phase 2 trial, ongoing and planned regulatory interactions, and our financial resources and expected cash runway.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: delays or failure to successfully initiate or complete our ongoing and planned development activities for our product candidates, including PGN-EDODM1 and PGN-EDO51; our ability to enroll patients in our clinical trials, including FREEDOM, FREEDOM2 and CONNECT2; that our interpretation of clinical and preclinical study results may be incorrect, or that we may not observe the levels of therapeutic activity in clinical testing that we anticipate based on prior clinical or preclinical results, including for PGN-EDODM1 and PGN-EDO51; our product candidates, including PGN-EDODM1 and PGN-EDO51, may not be safe and effective or otherwise demonstrate safety and efficacy in our clinical trials; adverse outcomes from our regulatory interactions, including delays in regulatory review, clearance to proceed or approval by regulatory authorities with respect to our programs, including clearance to commence planned clinical studies of our product candidates, or other regulatory feedback requiring modifications to our development programs, including in each case with respect to our FREEDOM, FREEDOM2, CONNECT1 and CONNECT2 clinical trials; changes in regulatory framework that are out of our control; unexpected increases in the expenses associated with our development activities or other events that adversely impact our financial resources and cash runway; and our dependence on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen's programs and operations are described in our most recent annual report on Form 10-K and quarterly report on Form 10-Q that are filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
This release discusses PGN-EDODM1 and PGN-EDO51, investigational therapies that have not been approved for use in any country and is not intended to convey conclusions about their efficacy or safety. There is no guarantee that PGN-EDODM1, PGN-EDO51 or any other investigational therapy will successfully complete clinical development or gain regulatory authority approval.
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
ReElement Technologies Corporation Receives $150 Million Letter of Interest from United States EXIM Bank to Advance the Nation's Largest Critical Mineral Refinery
Marion Advanced Technology Center positioned to become the largest multi-mineral, multi-feedstock rare earth and critical mineral refinery in the United States EXIM's support of the proposed capital funding plan for the Marion Advanced Technology Center advances the "Make More In America" initiative amid rising competition from China in critical mineral supply chains FISHERS, IN / / June 9, 2025 / American Resources Corporation (NASDAQ:AREC) ("American Resources"), through its holding in ReElement Technologies Corporation ("ReElement" or "RTC"), a leading U.S. innovator in rare earth element (REE) and critical mineral refining, announced today that it has received support for the proposed capital funding plan by ReElement Technologies Corporation for the Marion Advanced Technology through a Letter of Interest (LOI) from the Export-Import Bank of the United States (EXIM) for up to $150 million in financing. This financing will support the expansion of ReElement's state-of the-art rare earth, critical mineral and defense mineral refining project that is set to become the nation's largest multi-mineral, multi-feedstock rare earth and critical mineral refinery. The Marion facility builds on ReElement's successful commercial operations in its Noblesville, Indiana facility supplying highly refined critical mineral products to both the commercial and defense markets. ReElement's Advanced Separation Platform Aligned with National Mandate for Mineral Independence ReElement Technologies' rare earth element (REE) separation process - based on its patented and proprietary chromatography-based refining methods - represents a transformative leap forward in strengthening the U.S. industrial base for critical minerals. This innovative platform directly supports Presidential Executive Orders focused on restoring mineral independence and securing national supply chains. ReElement's process consistently produces ultra-high-purity (99.5%+) rare earth oxides and compounds such as neodymium, dysprosium, terbium, gallium, antimony, samarium, yttrium, gadolinium, and others - key materials required for metallization, magnet production, and advanced technologies across defense and commercial applications. Mark Jensen, CEO of ReElement Technologies commented, "We're honored to receive positive support from the Export-Import Bank of the United States. Our team has worked tirelessly to validate our next-generation refining platform and strategically scale production to meet the growing needs of both commercial and defense sectors. From day one, our vision has been clear: the U.S. must regain control of the midstream segment of the critical mineral supply chain if we are to compete globally. Support from the federal government significantly accelerates the buildout of additional refining capacity at our 42-acre Marion campus and beyond. We are laser-focused on scaling up production of refined rare earth oxides and defense-grade mineral compounds that are urgently needed here at home. As we see it, ReElement is among the only - if not the only - commercial entity in the United States capable of producing these materials at quantities and cost structures that rival or even undercut the Chinese industrial base. We're excited to expand our footprint domestically and internationally, delivering long-term supply chain resilience and a diversified source of critical and rare earth elements." Federal Support Aligned with New Executive Action on U.S. Mineral Production The issuance of this Letter of Interest aligns with the March 20, 2025, Executive Order titled "Immediate Measures to Increase American Mineral Production". The order directs federal agencies, including EXIM, to streamline permitting, unlock financing, and establish offtake agreements for U.S.-based critical mineral processing facilities. It also sets near-term mandates for fast-tracking approvals, mobilizing capital, and stockpiling strategic materials vital to national defense, clean energy, and next-generation technology infrastructure. ReElement's Technological Edge: Chromatographic Separation and Purification ReElement employs continuous chromatography, a breakthrough in rare earth separation and purification that delivers: Aqueous Chemistry - Eliminates the need for toxic and hazardous organic solvents, making the process safer and more environmentally friendly. Lower Capital Expenditures - A few chromatography units can replace hundreds or even thousands of mixer-settlers to achieve the same throughput and product requirements. High Versatility - An intrinsic-parameter-based design and predictive simulation tools allow for rapid, adaptable refining across various feedstocks and production scales. Modular and Scalable Capacity - Easily expands processing volumes in alignment with growing feedstock availability. Localized Processing - Reduces the need for raw ore transportation across the globe, strengthening supply chain security and efficiency. ReElement's refining platform - originally developed by Purdue University for pharmaceutical purification - has been reengineered to separate rare earths and critical minerals with exceptional efficiency, scalability, and purity. Their patented, programmable platform handles multiple feedstocks and minerals, enabling rapid modular deployment across locations and resource types. Unlike legacy solvent extraction methods, it uses far fewer chemicals, requires less space, and generates minimal waste - making it faster to permit and simpler to co-locate near feedstock or end-use customers. This breakthrough eliminates a major chokepoint in global critical mineral supply chains, which has been dominated by single-source processing, no longer tenable as the U.S. must forge critical mineral supply chain independence, both through refining in the U.S. and in partnership with allies abroad. About ReElement Technologies Corporation ReElement Technologies Corporation is a leading provider of high-performance refining capacity for rare earth and critical battery elements. Its multi-mineral, multi-feedstock platform technology focuses on the refining of recycled material from rare earth permanent magnets and lithium-ion batteries, concentrated ores and brines, as well as coal-based waste streams and byproducts to create a cost effective and environmentally-safe, circular supply chain. ReElement has developed its innovative and scalable "Powered by ReElement" process which collaboratively utilizes its exclusively licensed intellectual property within its partners' material processing flow sheets to more efficiently support the global supply chain's growing demand for magnet and battery-grade products. For more information visit or connect with the Company on Facebook, Twitter, and LinkedIn. About American Resources Corporation (NASDAQ:AREC) American Resources Corporation is a leader in the critical mineral supply chain, developing innovative solutions both upstream and downstream of the refining process. The company and its affiliates focus on the extraction and processing of metallurgical carbon and iron ore, essential ingredients in steelmaking, as well as critical and rare earth minerals for the electrification market and recycled metals. Leveraging its affiliation and former parent status of ReElement Technologies Corporation, a leading provider of high-performance refining capacity for rare earth and critical battery elements, American Resources is investing in and developing efficient upstream and downstream critical mineral operations. These operations include mining interests in conventional and unconventional sources, recycling, and manufacturing. American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. For more information visit or connect with the Company on Facebook, Twitter, and LinkedIn. Special Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved. Investor Contact:JTC Team, LLCJenene Thomas(908) 824 - 0775arec@ Media Inquiries:Marjorie Weisskohl703-587-1532mweisskohl@ Company Contact:Mark LaVerghetta317-855-9926 ext. 0investor@ SOURCE: American Resources Corporation View the original press release on ACCESS Newswire
Business Wire
25 minutes ago
- Business Wire
Anodyne Nanotech Drives Major Advancement in the Treatment of Sarcopenia with Novel Muscle-Preserving Therapy
BOSTON--(BUSINESS WIRE)--Anodyne Nanotech, a clinical-stage biotech company, today announced new preclinical data demonstrating that administration of ANN-102 - an APJ receptor agonist via its proprietary HeroPatch™ microneedle system - significantly improved muscle strength, with efficacy equivalent to daily injections. These results lay the foundation for a novel, non-invasive, muscle-preserving therapy aimed at addressing sarcopenia, a major health challenge in aging populations. Beginning at age 30, people lose on average 3–8% of their muscle mass per decade, and this accelerates after age 60. By the time individuals reach their 80s or 90s, up to 50% of their muscle mass may be lost, particularly in those who are inactive. This deterioration extends beyond reduced strength; it increases vulnerability to chronic diseases, falls, fractures, hospitalization and loss of independence. Population studies have shown that muscle wasting is associated with up to a 36% increase in all-cause mortality, and it is a critical risk factor in cardiovascular disease, cancer, respiratory illness, and metabolic decline. Beyond its clinical toll, sarcopenia places a substantial economic burden on healthcare systems. In the United States alone, hospitalizations related to sarcopenia in adults over 65 cost an estimated $19.1 billion annually, underscoring the urgent need for scalable, preventive interventions that can help preserve muscle mass and physical function as people age. By targeting the APJ receptor, Anodyne's ANN-102 engages a powerful pathway implicated in several aging-related processes. Activation of this receptor has been shown to stimulate muscle stem cell activity and vascular repair, supporting muscle regeneration and directly addressing sarcopenia. It also improves insulin sensitivity, enhances mitochondrial function, promotes fat oxidation, and helps regulate appetite—offering metabolic benefits particularly relevant in older adults. Additionally, APJ receptor activation has demonstrated cardioprotective effects, including reduced myocardial damage and improved vascular function. Taken together, these effects position the APJ pathway as a promising therapeutic target for extending healthspan and addressing the systemic decline associated with aging. In a 20-day study in an aged mouse model, ANN-102 significantly increased grip strength, a common marker of functional muscle performance and a powerful predictor of overall longevity. The treatment was as effective as daily injections with an endogenous APJ RA, demonstrating the potential for a first non-invasive, sustained delivery. Full data will be presented later this year. 'These preclinical results continue to demonstrate the HeroPatch's ability to deliver complex therapies through the skin in a clinically meaningful way,' said Jake Lombardo, Anodyne's CEO and Co-Founder. 'We have developed an alternative route of administration for molecules that have strong therapeutic potential but have been held back by delivery challenges. This can make life-changing therapies accessible to patients for the first time.' Anodyne's lead asset is a once-weekly transdermal GLP-1 patch for obesity, entering clinical trials in 2026. While GLP-1 receptor agonists like semaglutide (Wegovy®) and tirzepatide (Zepbound®) have demonstrated significant weight loss benefits, emerging research has raised concerns about their impact on muscle mass. Studies indicate that up to 40% of weight lost on GLP-1 therapies may come from lean body mass, including muscle tissue, particularly in older adults or those with low baseline muscle reserves. Given Anodyne's ability to co-formulate multiple therapeutic agents in a single patch, there is substantial potential to combine GLP-1-based therapies with muscle-preserving agents like an APJ-RA in a single, patient-friendly patch—addressing both obesity and sarcopenia in an integrated approach to healthy aging. Based on these encouraging preclinical results, Anodyne will advance the APJ-RA program toward clinical development. The company is open to strategic partnerships and co-development opportunities to accelerate the path toward delivering this promising muscle-preserving therapy to patients worldwide. About Anodyne Nanotech Anodyne Nanotech develops novel therapies by combining proven molecules with its proprietary HeroPatch technology. Designed to simplify chronic disease management, the HeroPatch has the potential to reduce side effects, eliminate refrigeration requirements, and improve clinical outcomes. The company is advancing multiple assets into clinical development for conditions such as diabetes, obesity, autoimmune diseases, and oncology. For more information, visit
Business Wire
25 minutes ago
- Business Wire
Form 8.3 - Revolution Beauty Group Plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) Full name of discloser: cosnova Beauty GmbH (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. See 1(a) (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Revolution Beauty Group Plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 4 June 2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state 'N/A' N/A Expand 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Ordinary Shares (GB00BP7L1T61) Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 9,250,000 2.89 ./. (2) Cash-settled derivatives: ./. ./. (3) Stock-settled derivatives (including options) and agreements to purchase/sell: ./. ./. TOTAL: 9,250,000 2.89 ./. Expand All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: N/A Details, including nature of the rights concerned and relevant percentages: N/A Expand 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Expand (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit Expand (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit Expand (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit Expand (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) Expand 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none' none Expand (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state 'none' none Expand (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Expand Date of disclosure: 4 June 2025 Contact name: Stephan Klinke Telephone number*: Expand Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit. The Code can be viewed on the Panel's website at
